ATE290864T1 - Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotamin - Google Patents
Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotaminInfo
- Publication number
- ATE290864T1 ATE290864T1 AT98109002T AT98109002T ATE290864T1 AT E290864 T1 ATE290864 T1 AT E290864T1 AT 98109002 T AT98109002 T AT 98109002T AT 98109002 T AT98109002 T AT 98109002T AT E290864 T1 ATE290864 T1 AT E290864T1
- Authority
- AT
- Austria
- Prior art keywords
- dihydroergotamin
- pharmaceutical compositions
- intranasal administration
- dihydroergotaminesalt
- dihydroergotamine
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 abstract 1
- 229960004704 dihydroergotamine Drugs 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE9300298A BE1006871A6 (nl) | 1993-03-26 | 1993-03-26 | Nasale farmaceutische preparaten met apomorfine. |
| BE9300299A BE1006872A6 (nl) | 1993-03-26 | 1993-03-26 | Nasale farmaceutische preparaten met dihydroergotamine (dhe). |
| BE9300297A BE1006870A6 (nl) | 1993-03-26 | 1993-03-26 | Nasale farmaceutische preparaten met morfine. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE290864T1 true ATE290864T1 (de) | 2005-04-15 |
Family
ID=27159799
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98109002T ATE290864T1 (de) | 1993-03-26 | 1994-03-18 | Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotamin |
| AT94911944T ATE241984T1 (de) | 1993-03-26 | 1994-03-18 | Pharmazeutische zusammensetzungen zur intranasalen verabreichung von apomorphin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94911944T ATE241984T1 (de) | 1993-03-26 | 1994-03-18 | Pharmazeutische zusammensetzungen zur intranasalen verabreichung von apomorphin |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5756483A (de) |
| EP (2) | EP0689438B1 (de) |
| JP (2) | JPH08508472A (de) |
| AT (2) | ATE290864T1 (de) |
| AU (1) | AU6428894A (de) |
| DE (2) | DE69434304T2 (de) |
| DK (2) | DK0865789T3 (de) |
| ES (2) | ES2194867T3 (de) |
| PT (2) | PT865789E (de) |
| WO (1) | WO1994022445A2 (de) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395744B1 (en) | 1994-04-22 | 2002-05-28 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
| US6121276A (en) | 1994-04-22 | 2000-09-19 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
| CA2188385C (en) * | 1994-04-22 | 2000-07-11 | Ragab El-Rashidy | Dosage forms and method for ameliorating male erectile dysfunction |
| US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
| JPH11503750A (ja) * | 1995-04-17 | 1999-03-30 | サンチェズ，ロバート | ウルシオールの錯体化 |
| GB9517062D0 (en) | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
| US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| EP0834308A1 (de) * | 1996-09-30 | 1998-04-08 | LG Chemical Limited | Ophthalmische Zubereitung zur Behandlung von Kurzsichtigkeit enthaltend einen Dopaminagonisten und Cyclodextrin |
| US5855907A (en) * | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
| US8631796B2 (en) | 1997-04-10 | 2014-01-21 | Cookgas, L.L.C. | Laryngeal mask |
| EP1035833B1 (de) * | 1997-12-02 | 2005-08-31 | Archimedes Development Limited | Zusammensetzungen zur nasalen verabreichung |
| DE69901936T2 (de) * | 1998-01-30 | 2002-11-28 | Novartis Consumer Health S.A., Nyon | Nasale lösungen |
| US6403605B1 (en) | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
| US6436950B1 (en) * | 1998-08-14 | 2002-08-20 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
| US20020002175A1 (en) * | 2000-09-19 | 2002-01-03 | Charanjit Behl | Nasal delivery of apomorphine in combination with glycol derivatives |
| WO2000023023A1 (en) * | 1998-10-20 | 2000-04-27 | The University Of North Carolina At Chapel Hill | Methods of hydrating mucosal surfaces |
| US6291471B1 (en) | 1998-12-17 | 2001-09-18 | Abb Holdings, Inc. | Use of apomorphine for the treatment of organic erectile dysfunction in males |
| JP2003501467A (ja) * | 1999-06-16 | 2003-01-14 | ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド | 鼻内モルヒネを含む医薬用製剤および方法 |
| US6225343B1 (en) * | 1999-06-16 | 2001-05-01 | Nastech Pharmaceutical Company, Inc. | Compositions and methods comprising morphine gluconate |
| GB9924797D0 (en) * | 1999-10-20 | 1999-12-22 | West Pharm Serv Drug Res Ltd | Compound |
| HUP0400495A3 (en) * | 1999-12-30 | 2007-05-02 | Tap Pharmaceutical Prod Inc | Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue |
| US6506765B2 (en) | 2000-04-07 | 2003-01-14 | Tap Pharmaceutical Products, Inc. | Apomorphine derivatives and methods for their use |
| US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
| DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| JP2004513899A (ja) * | 2000-11-15 | 2004-05-13 | タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド | 抗鬱薬誘発性的機能不全のアポモルヒネによる治療 |
| US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
| US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
| US20030198669A1 (en) * | 2001-07-05 | 2003-10-23 | R.T. Alamo Ventures I, Llc | Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine |
| US20030017175A1 (en) * | 2001-07-05 | 2003-01-23 | R.T. Alamo Ventures I, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
| US6685951B2 (en) | 2001-07-05 | 2004-02-03 | R. T. Alamo Ventures I, Inc. | Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine |
| US20030187011A1 (en) * | 2001-12-20 | 2003-10-02 | Lashuel Hilal A. | Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease |
| US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| KR20050008658A (ko) * | 2002-03-19 | 2005-01-21 | 마이클 홀릭 | 아포모르핀의 글리코시드 및 오르토에스테르 글리코시드유도체들, 유사체들 및 그것의 용도 |
| EP1355158A1 (de) * | 2002-04-19 | 2003-10-22 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur Diagnose von Entzündungserkrankungen und Infektionen unter Bestimmung des Phosphoproteins LASP-1 als Inflammationsmarker |
| US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
| PT2561860T (pt) * | 2002-05-31 | 2018-05-08 | Titan Pharmaceuticals Inc | Dispositivo polimérico implantável para a libertação prolongada de buprenorfina |
| US8840928B2 (en) | 2002-07-05 | 2014-09-23 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| US8557291B2 (en) | 2002-07-05 | 2013-10-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
| JP4694207B2 (ja) | 2002-07-05 | 2011-06-08 | コルジウム ファーマシューティカル， インコーポレイテッド | オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物 |
| US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| US7638138B2 (en) | 2003-02-21 | 2009-12-29 | Translational Research, Ltd. | Compositions for nasal administration of pharmaceuticals |
| GB0304636D0 (en) * | 2003-02-28 | 2003-04-02 | Britannia Pharmaceuticals Ltd | Pharmaceutical composition for nasal delivery |
| WO2004087243A1 (ja) | 2003-03-27 | 2004-10-14 | Bioactis Limited | 鼻腔用粉末薬剤施薬装置 |
| CA2520613C (en) | 2003-03-31 | 2012-12-04 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of dopamine agonist |
| RU2364400C2 (ru) * | 2003-04-14 | 2009-08-20 | Вектура Лтд | Фармацевтические композиции |
| US20060147389A1 (en) * | 2004-04-14 | 2006-07-06 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
| US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
| FR2857594B1 (fr) * | 2003-07-17 | 2005-09-16 | Servier Lab | Composition pharmaceutique pour l'administration par voie nasale de piribedil |
| AU2004272077A1 (en) * | 2003-09-10 | 2005-03-24 | Map Pharmaceuticals, Inc. | Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
| US20050090518A1 (en) * | 2003-10-24 | 2005-04-28 | Nastech Pharmaceutical Company Inc. | Method for treating parkinson's disease using apomorphine and apomorphine prodrugs |
| EP1547592A1 (de) * | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasale formulierung enthaltend |
| US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US20070020196A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
| US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
| BRPI0418276B8 (pt) | 2003-12-31 | 2021-05-25 | Cydex Pharmaceuticals Inc | formulação líquida inalável compreeendendo budesonida |
| ATE446581T1 (de) * | 2004-03-12 | 2009-11-15 | Trinity College Dublin | Magnetoresistives medium |
| PL2708225T3 (pl) | 2004-04-23 | 2019-07-31 | Cydex Pharmaceuticals, Inc. | Formulacja DPI zawierająca eter sulfoalkilowy cyklodekstryny |
| EP1765292B1 (de) * | 2004-06-12 | 2017-10-04 | Collegium Pharmaceutical, Inc. | Gegen missbrauch gesicherte arzneimittelformulierungen |
| WO2006016530A1 (ja) * | 2004-08-10 | 2006-02-16 | Translational Research, Ltd. | 速効性でかつ高い吸収性を可能とする経鼻投与用組成物 |
| GB0509317D0 (en) * | 2005-05-06 | 2005-06-15 | Clarke Anthony | Pharmaceutical formulation of apomorphine |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| US20070185066A1 (en) * | 2005-12-20 | 2007-08-09 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
| US20070249572A1 (en) * | 2005-12-20 | 2007-10-25 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
| US20070160542A1 (en) * | 2005-12-20 | 2007-07-12 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
| US20070197486A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids |
| US20070178049A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
| WO2007095341A2 (en) * | 2006-02-15 | 2007-08-23 | Tika Läkemedel Ab | Sterilization of corticosteroids with reduced mass loss |
| GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
| ES2652415T3 (es) | 2006-12-26 | 2018-02-02 | Shin Nippon Biomedical Laboratories, Ltd. | Preparación para aplicación transnasal |
| SG177217A1 (en) * | 2007-01-17 | 2012-01-30 | Devirex Ag | Cyclodextrin formulations |
| DK2425820T3 (en) * | 2007-02-11 | 2015-07-13 | Map Pharmaceuticals Inc | A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile |
| EP1987815A1 (de) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Im Mund-Nasen-Rachenraum verabreichbare pharmazeutische Zusammensetzungen enthaltend Dopaminagonisten zur Vorbeugung und/oder Behandlung von unruhigen Gliedmassen |
| US20110111014A1 (en) * | 2007-06-26 | 2011-05-12 | Parkinson's Institute | Methods and compositions for treatment of neurological disorders |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| GB0715285D0 (en) * | 2007-08-06 | 2007-09-12 | Britannia Pharmaceuticals Ltd | Improvements in or relating to powdered medicaments for nasal delivery |
| WO2009040595A1 (en) * | 2007-09-28 | 2009-04-02 | Wockhardt Research Centre | Multi-dose pharmaceutical composition of analgesic for nasal administration |
| GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
| EP2057982A1 (de) * | 2007-11-09 | 2009-05-13 | Archimedes Development Limited | Intranasale Zusammensetzungen |
| US8054177B2 (en) * | 2007-12-04 | 2011-11-08 | Avaya Inc. | Systems and methods for facilitating a first response mission at an incident scene using patient monitoring |
| EP2429495A4 (de) * | 2009-05-15 | 2014-01-22 | Shin Nippon Biomedical Lab Ltd | Intranasale pharmazeutische zusammensetzung mit verbesserter pharmakokinetik |
| GB2472327B (en) * | 2009-07-31 | 2013-03-13 | Shin Nippon Biomedical Lab Ltd | Intranasal granisetron and nasal applicator |
| US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| TW201304822A (zh) | 2010-11-15 | 2013-02-01 | Vectura Ltd | 組成物及用途 |
| EP2545905A1 (de) * | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | Neue therapeutische Zusammensetzung mit Apomorphin als aktiver Inhaltsstoff |
| AU2012386221A1 (en) | 2012-07-26 | 2015-02-26 | Wockhardt Limited | Pharmaceutical composition comprising diamorphine for intranasal administration |
| CA2895816C (en) | 2012-12-21 | 2021-02-23 | Map Pharmaceuticals, Inc. | 8'-hydroxy-dihydroergotamine compounds and compositions |
| WO2015044782A2 (en) * | 2013-09-24 | 2015-04-02 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal dhe for the treatment of headache |
| NZ741171A (en) | 2015-09-10 | 2022-01-28 | Impel Neuropharma Inc | In-line nasal delivery device |
| WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
| US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
| JP7317020B2 (ja) | 2018-01-05 | 2023-07-28 | インペル ファーマシューティカルズ インコーポレイテッド | 精密嗅覚デバイスによるジヒドロエルゴタミンの鼻腔内送達 |
| EP3893877A4 (de) | 2018-12-11 | 2022-09-14 | Satsuma Pharmaceuticals, Inc. | Zusammensetzungen, vorrichtungen und verfahren zur behandlung oder vorbeugung von kopfschmerzen |
| GB2581431A (en) * | 2018-12-11 | 2020-08-19 | Satsuma Pharmaceuticals Inc | Compositions, devices, and methods for treating or preventing headaches |
| US11786512B2 (en) | 2019-09-23 | 2023-10-17 | Slayback Pharma Llc | Stable pharmaceutical compositions of dihydroergotamine mesylate |
| WO2022009248A1 (en) * | 2020-07-07 | 2022-01-13 | Jordan University Of Science And Technology | A pharmaceutical composition for treating migraine headaches and a cosolvent method of preparation thereof |
| IT202100009857A1 (it) | 2021-04-19 | 2022-10-19 | Univ Degli Studi Di Torino | Formulazione a rilascio controllato e prolungato di apomorfina |
| EP4398908A4 (de) * | 2021-09-12 | 2025-09-24 | Gmp Biotechnology Ltd | Behandlung von neurologischen erkrankungen |
| CN115804754A (zh) * | 2022-12-16 | 2023-03-17 | 广州新济药业科技有限公司 | 吗啡鼻喷剂及其制备方法 |
| GB2634218A (en) * | 2023-09-29 | 2025-04-09 | Approved Pharma Solutions Ltd | Powder for oral solution formulations |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2750090A1 (de) * | 1976-11-19 | 1978-06-01 | Sandoz Ag | Neue verabreichungsformen fuer organische verbindungen |
| US5169849A (en) * | 1982-02-01 | 1992-12-08 | Sandoz Ltd. | Nasal pharmaceutical compositions |
| DE3372705D1 (en) * | 1982-04-30 | 1987-09-03 | Takeda Chemical Industries Ltd | Pharmaceutical composition and its use |
| US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| GB8514665D0 (en) * | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
| GB8613688D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| US5624898A (en) * | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
| SE8904295D0 (sv) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Smoking substitute |
| GB9012663D0 (en) * | 1990-06-07 | 1990-08-01 | Erba Carlo Spa | Galenic formulations containing cyclodextrins |
| ATE112491T1 (de) * | 1990-09-13 | 1994-10-15 | Akzo Nobel Nv | Stabilisierte feste chemische zusammensetzungen. |
| US5169840A (en) * | 1991-03-27 | 1992-12-08 | Nobipols Forskningsstiftelse | Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation |
| GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| DE4207922A1 (de) * | 1992-03-13 | 1993-09-23 | Pharmatech Gmbh | Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung |
| US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| US5506203C1 (en) * | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
-
1994
- 1994-03-18 DE DE69434304T patent/DE69434304T2/de not_active Expired - Lifetime
- 1994-03-18 ES ES94911944T patent/ES2194867T3/es not_active Expired - Lifetime
- 1994-03-18 EP EP94911944A patent/EP0689438B1/de not_active Expired - Lifetime
- 1994-03-18 JP JP6521631A patent/JPH08508472A/ja active Pending
- 1994-03-18 EP EP98109002A patent/EP0865789B1/de not_active Expired - Lifetime
- 1994-03-18 AU AU64288/94A patent/AU6428894A/en not_active Abandoned
- 1994-03-18 US US08/525,771 patent/US5756483A/en not_active Expired - Lifetime
- 1994-03-18 AT AT98109002T patent/ATE290864T1/de active
- 1994-03-18 ES ES98109002T patent/ES2239369T3/es not_active Expired - Lifetime
- 1994-03-18 DK DK98109002T patent/DK0865789T3/da active
- 1994-03-18 DK DK94911944T patent/DK0689438T3/da active
- 1994-03-18 PT PT98109002T patent/PT865789E/pt unknown
- 1994-03-18 DE DE69432789T patent/DE69432789T2/de not_active Expired - Lifetime
- 1994-03-18 PT PT94911944T patent/PT689438E/pt unknown
- 1994-03-18 WO PCT/EP1994/000891 patent/WO1994022445A2/en not_active Ceased
- 1994-03-18 AT AT94911944T patent/ATE241984T1/de active
-
1998
- 1998-04-17 US US09/062,633 patent/US5942251A/en not_active Expired - Lifetime
-
2004
- 2004-10-06 JP JP2004293322A patent/JP2005041884A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0865789A2 (de) | 1998-09-23 |
| EP0865789B1 (de) | 2005-03-16 |
| DE69434304D1 (de) | 2005-04-21 |
| JP2005041884A (ja) | 2005-02-17 |
| DK0865789T3 (da) | 2005-07-18 |
| PT865789E (pt) | 2005-05-31 |
| DE69434304T2 (de) | 2005-12-29 |
| DK0689438T3 (da) | 2003-09-29 |
| ATE241984T1 (de) | 2003-06-15 |
| ES2239369T3 (es) | 2005-09-16 |
| EP0689438A1 (de) | 1996-01-03 |
| DE69432789D1 (de) | 2003-07-10 |
| WO1994022445A3 (en) | 1995-01-05 |
| ES2194867T3 (es) | 2003-12-01 |
| JPH08508472A (ja) | 1996-09-10 |
| PT689438E (pt) | 2003-10-31 |
| EP0689438B1 (de) | 2003-06-04 |
| WO1994022445A2 (en) | 1994-10-13 |
| US5942251A (en) | 1999-08-24 |
| US5756483A (en) | 1998-05-26 |
| AU6428894A (en) | 1994-10-24 |
| DE69432789T2 (de) | 2003-12-04 |
| EP0865789A3 (de) | 1999-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69434304D1 (de) | Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin | |
| YU59092A (sh) | Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja | |
| MX9203480A (es) | Formulaciones medicinales en aereosol. | |
| DE69622735D1 (de) | Lyophilisierte stabile pharmazeutische formulierung | |
| FI955583A7 (fi) | Nikotiinia sisältävä nasaalinen lääkkeenjakelukoostumus | |
| DK0625046T3 (da) | Farmaceutiske aerosolformuleringer indeholdende beclomethasondipropionat | |
| YU59192A (sh) | Formulacija aerosola koje ne sadrže hlorofluorougljenična jedinjenja | |
| BR9606674B1 (pt) | novo derivado de composto de antraciclina e preparação farmacêutica contendo o mesmo. | |
| DE68905886D1 (de) | Calcitoninzusammensetzung zur intranasalen verabreichung. | |
| DE68918847D1 (de) | Stabile pharmazeutische zusammensetzung. | |
| AU6094690A (en) | Long active injectable formulations containing triacetin | |
| FI944770L (fi) | Neurotensiiniin vaikuttavia substituoituja 1-naftyylipyratsoli-3-karboksiamideja, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia | |
| IL97251A0 (en) | Antihypercholesterolemic 2,8-dioxabicyclo(3,2,1)octane derivatives,their preparation and pharmaceutical compositions containing them | |
| EP1108717A3 (de) | C7-Taxan-Derivate und diese enthaltende pharmazeutische Zusammenstellungen | |
| FR2712191B1 (fr) | Composition pharmaceutique ou diététique associant du ginseng et du guarana. | |
| DE68912341D1 (de) | Pharmazeutische zusammensetzungen mit gehalt an calcitonin zur intranasalen verabreichung und eine spray-einheit zur verabreichung derselben. | |
| DE68902300D1 (de) | Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure. | |
| FI960487A7 (fi) | Bentsopyraaneja ja niitä sisältäviä farmaseuttisia koostumuksia | |
| WO2000027430A3 (de) | Zusammensetzung bestehend aus influenzavirusoberflächenprotein, und abgabeeinrichtung | |
| DE69012031D1 (de) | Optisch aktive Benzylalkoholverbindung und pharmazeutische Zusammensetzung. | |
| DK0588177T3 (da) | Interferon-alpha/beta-bindende protein, fremstilling heraf samt farmaceutiske præparater indeholdende proteinet | |
| ATE231728T1 (de) | Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren | |
| FR2594714B1 (fr) | Dispositif distributeur-diffuseur de substances volatiles, notamment de desodorisants d'atmosphere | |
| ATE211383T1 (de) | Topische aciclovir-zubereitung | |
| ATE201996T1 (de) | Hirudin enthaltende pharmazeutische zusammensetzungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0865789 Country of ref document: EP |